AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$ORKA

Goncalves Joana sold $734K of ORKA

Goncalves Joana (Chief Medical Officer) sold 7,947 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.38 ($91.10–$95.71, $0.73M total) across 5 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Goncalves Joana
Published Sep 15, 2026, 11:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Neutral
high confidence
Mentioned
$ORKA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKANeutralLow
01

Why it matters

The sale is unlikely to move the stock; investors may monitor for larger insider trends.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential upcoming FDA filing or trial results not disclosed in the filing.

Relevance 4/10Novelty 2/10Timing: same‑day filing

Background

Form 4 filing by Oruka Therapeutics' CMO discloses a modest share sale under a pre‑arranged plan.

Company-level read

Ticker impact

$ORKANeutralHigh confidence
Context

Chief Medical Officer sold 7,947 shares for $734K via a 10b5‑1 plan, reducing her stake to 31,771 shares.

Expected impact

Likely negligible price effect; no immediate trading bias.

Evidence & confidence

The transaction is a routine 10b5‑1 sale of under $1M, typical for insiders; market impact is minimal.

Market effects

Sector

No material impact on biotech sector; insider activity is routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a pre‑emptive move ahead of upcoming clinical data, suggesting caution.

Key entities

  • Company
    Oruka Therapeutics, Inc.

    Biotech firm developing therapies.

  • Insider
    Goncalves Joana

    Chief Medical Officer of Oruka Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 27
$ORKAHighAI 8/10

H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for Oruka Therapeutics (ORKA) after positive Phase 2b trial results for ORKA-001 in psoriasis. The stock rose 14% last week to $90.33, up 226% over a year. Analysts' price targets range from $117 to $200. The trial showed 61% of high-dose patients achieved PASI 100 at Week 16. Phase 3 trials are planned for 2027.

investing.com2 min
OCT 27
$ORKAMedAI 8/10

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics reported that its drug ORKA-001 achieved 61% complete skin clearance in a Phase IIb psoriasis study. The company plans to advance the 600-milligram dose into Phase III in early 2027, pending regulatory discussions. Oruka also expects to report week 52 data from the EVERLAST-A study in December, which will test the drug's potential for annual maintenance dosing. The company has over $1 billion in cash, providing runway through a potential biologics license application filing.

finance.yahoo.com2 min